Veterinary Orthobiologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

The Global Veterinary Orthobiologics Market is projected to expand from USD 787.27 Million in 2025 to USD 1.31 billion by 2031, achieving a CAGR of 8.89%. Veterinary orthobiologics encompass biological substances like stem cells, platelet-rich plasma, and bone grafts, which veterinarians use to regenerate tissue and repair injured tendons, ligaments, and bones. The market's growth is primarily fueled by the increasing prevalence of osteoarthritis in aging companion animals and a growing willingness among pet owners to pay for premium healthcare services. This demand for advanced medical intervention is evidenced by significant industry expenditure; according to the American Pet Products Association, sales for veterinary care and products in the United States hit 39.8 billion dollars in 2024, highlighting the financial commitment supporting the adoption of regenerative therapies.

However, the market faces a substantial hurdle regarding the high costs associated with these treatments. Many orthobiologic procedures remain financially out of reach for the average pet owner, and the scarcity of comprehensive insurance coverage for regenerative therapies in specific regions further restricts accessibility. Consequently, these financial constraints constitute a major challenge that could limit the widespread implementation of these solutions and decelerate the overall momentum of market growth.

Market Drivers

The escalating prevalence of veterinary musculoskeletal and orthopedic disorders, significantly worsened by rising rates of pet obesity, acts as a primary catalyst for market expansion. As companion animals carry excess weight, mechanical stress on their joints increases, resulting in a higher frequency of osteoarthritis and ligament injuries that necessitate regenerative interventions. Data from the Association for Pet Obesity Prevention's '2024 Pet Obesity & Nutrition Opinion Survey', released in April 2025, indicates that 35% of dog owners and 33% of cat owners classified their pets as overweight or obese, representing a troubling year-over-year rise. This upward trend in weight-related health issues directly correlates with the surging demand for orthobiologic therapies, such as stem cells and platelet-rich plasma, which provide effective management for chronic joint deterioration.

Concurrently, the growing trend of pet humanization is fundamentally transforming the economic landscape of veterinary care. Owners increasingly regard their pets as essential family members, fueling a willingness to pursue advanced, frequently expensive medical treatments to ensure longevity and quality of life. The American Pet Products Association's '2025 State of the Industry Report', published in March 2025, reveals that pet ownership has broadened significantly, with 94 million U.S. households now owning at least one pet. This expanding base of dedicated owners creates the necessary market scale for sustained investment in novel regenerative technologies. Illustrating this rapid sector innovation, Gallant Therapeutics secured 18 million dollars in Series B funding in July 2025 to hasten the commercialization of its off-the-shelf stem cell therapies, underscoring strong financial confidence in the future of veterinary orthobiologics.

Market Challenges

The prohibitive cost of treatment represents a major obstacle to the expansion of the veterinary orthobiologics sector. These regenerative therapies frequently entail complex processing and specialized application, leading to high prices that are generally passed directly to the pet owner. Because veterinary healthcare in many primary markets operates predominantly on a fee-for-service basis, these significant out-of-pocket expenses often make such options inaccessible to the average client. This financial reality effectively confines the addressable market to a narrow demographic of affluent pet owners, preventing the procedure volume required to drive rapid industry growth.

This economic barrier is severely aggravated by the limited penetration of pet health insurance, which fails to bridge the affordability gap for most households. Without comprehensive coverage to offset these expenses, the market struggles to transition from niche usage to mass adoption. According to the North American Pet Health Insurance Association, the total number of insured pets in North America reached 7.03 million in 2025. This figure suggests that the vast majority of owners lack the financial safety net needed to fund premium regenerative procedures, directly dampening market volume and revenue velocity.

Market Trends

The market is observing a significant Shift Toward Allogeneic "Off-the-Shelf" Stem Cell Therapies, propelled by the urgent requirement for scalable, standardized treatments for common inflammatory diseases. In contrast to autologous methods that necessitate surgical extraction and processing, these manufactured therapies provide immediate availability and consistent dosing, meeting high-volume clinical needs in general practice. This demand is heavily underscored by the prevalence of difficult-to-treat conditions requiring advanced intervention; according to a July 2025 DVM360 article titled 'Veterinary stem cell therapy advances toward FDA approval with $18M in funding', refractory feline chronic gingivostomatitis alone affects up to 26% of domestic cats, creating a substantial addressable market for these novel, ready-to-use regenerative solutions.

Simultaneously, there is a distinct Expansion of Regenerative Medicine in Equine Sports Performance, where orthobiologics are becoming standard protocols for managing athletic injuries. High-value performance horses demand rapid, effective recovery strategies for tendon and ligament issues, prompting specialized veterinary centers to integrate these therapies into their core services to prolong competitive careers. Highlighting this increasing adoption rate within elite facilities, a VetStem press release from October 2025 titled 'Tryon Equine Hospital Surpasses 200 VetStem Regenerative Medicine Cases' noted that a single leading equine referral center successfully completed over 200 regenerative procedures, signaling broader industry acceptance and the commercial viability of these treatments in the equine sector.

Key Players Profiled in the Veterinary Orthobiologics Market

• Zoetis Services LLC
• Boehringer Ingelheim International GmbH
• Ardent Animal Health
• Enso Discoveries, LLC
• VetStem, Inc.
• MEDREGO LLC
• Arthrex, Inc.
• Hilltop Biosciences
• Enovis Corporation
• Dechra Pharmaceuticals Limited

Report Scope

In this report, the Global Veterinary Orthobiologics Market has been segmented into the following categories:

Veterinary Orthobiologics Market, by Product:

• Stem Cells
• Platelet-rich Plasma (PRP)
• Other

Veterinary Orthobiologics Market, by Animal:

• Canine
• Equine
• Others

Veterinary Orthobiologics Market, by Application:

• Osteoarthritis
• Degenerative Joint Disease
• Other

Veterinary Orthobiologics Market, by Delivery Mode:

• Intra-muscular/Intra-lesional
• Intra-articular
• Others

Veterinary Orthobiologics Market, by End User:

• Veterinary Hospitals
• Veterinary Clinics
• Others

Veterinary Orthobiologics Market, by Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Orthobiologics Market.

Available Customization

The analyst offers customization according to your specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.